Diabetes Drug Actos Linked to Pancreatic, Prostate Cancers in New Study

Just a few months after Takeda Pharmaceuticals settled claims for $2.37 million over its diabetes drug Actos allegedly causing bladder cancer, a new study suggests that the medication may also pose an increased risk of pancreatic and prostate cancers. Published in July 2015 in the Journal of American Medical Association, researchers found that after studying nearly 200,000 patients ages 40 and older, 11 different kinds of cancers were linked to Actos use. Pancreatic and prostate cancers were among the most likely, indicating that Actos could contribute to a 41% increased risk of developing pancreatic cancer and a 13% increased risk of prostate cancer, raising further concerns for patients and the medical community regarding the safety of Actos.

Real Time Analytics